Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Gains from Investment Securities (2016 - 2025)

Corcept Therapeutics' Gains from Investment Securities history spans 8 years, with the latest figure at -$23.4 million for Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 152.13% year-over-year to -$23.4 million; the TTM value through Dec 2025 reached $13.0 million, down 78.48%, while the annual FY2025 figure was $13.0 million, 78.48% down from the prior year.
  • Gains from Investment Securities for Q4 2025 was -$23.4 million at Corcept Therapeutics, down from $8.2 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $45.0 million in Q4 2024 and bottomed at -$23.4 million in Q4 2025.
  • The 5-year median for Gains from Investment Securities is $2.1 million (2021), against an average of $5.7 million.
  • The largest annual shift saw Gains from Investment Securities crashed 201.92% in 2021 before it soared 4417.69% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at -$11.2 million in 2021, then soared by 107.54% to $846000.0 in 2022, then increased by 17.61% to $995000.0 in 2023, then skyrocketed by 4417.69% to $45.0 million in 2024, then crashed by 152.13% to -$23.4 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Gains from Investment Securities are -$23.4 million (Q4 2025), $8.2 million (Q3 2025), and $12.4 million (Q2 2025).